Search Results - immunotherapy

136 Results Sort By:
IgA Monoclonal Antibodies as a Prophylactic and Therapeutic Treatment for Dengue Virus Infection
Enables the prevention and treatment of dengue by avoiding the challenge of Antibody Dependent Enhancement. Background: Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths. In addition, dengue-associated illness comprises...
Published: 4/1/2025   |   Inventor(s): Adam Waickman, Adam Wegman
Keywords(s): antibody, antibody therapy, biologics, biomedical, disease prevention, immunotherapy, monoclonal antibody, Technologies, viral immunology, viral pathogenesis
Category(s): Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Antibodies, Technology Classifications > Healthcare, Technology Classifications > Viral Vectors, Campus > Upstate Medical University
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Single-Chain Bispecific Chimeric Antigen Receptor Targeting BCMA and CS1 for the Treatment of Multiple Myeloma (UCLA Case No. 2018-680)
UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a single-chain bispecific chimeric antigen receptor targeting BCMA and CS1 for treating multiple myeloma. BACKGROUND: Multiple myeloma (MM) is a cancer of the plasma cells that accounts for over 30,000 new diagnoses each year, according to the American Cancer...
Published: 2/19/2025   |   Inventor(s): Yvonne Chen, Eugenia Zah
Keywords(s): Hematology, Immunotherapy, Life Science Research Tools, Therapeutics & Vaccines
Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Hematology
High-Throughput Approach to Identify New Lipid Nanoparticle Formulations for Vaccine and Drug Delivery
High-throughput in vivo screening method to identify lipid nanoparticle (LNP) formulations for local and systemic delivery for mRNA vaccines and cancer immunotherapies. Problem: Nucleic acid delivery is an attractive and rapidly growing area of research, particularly for the development of vaccines and cancer immunotherapy. Historically, viral vectors...
Published: 1/7/2025   |   Inventor(s): Michael Mitchell, Alex Hamilton
Keywords(s): Bioengineering, COVID-19, Drug Delivery, Gene Therapy, Immunology, Immunoncology, Immunotherapy, Infectious Disease, Nanotechnology
Category(s): Technology Classifications > Testing & Measurement, Technology Classifications > Vaccines, Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024   |   Inventor(s): Ann Metzloff, Margaret Billingsley, Michael Mitchell
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
3D Scaffold for T Cell Delivery and Suppression of Tregs for Solid Tumors (UCLA Case No. 2020-193)
SUMMARY: UCLA researchers in the Department of Bioengineering have developed a small and biodegradable implant that when placed adjacent to solid tumors, enhances immune response to cancer cells. BACKGROUND: The body’s immune system uses proteins called antibodies to train the immune response to foreign pathogens. This mechanism can combat...
Published: 2/14/2025   |   Inventor(s): Manish Butte
Keywords(s): cytokines, Drug Delivery, Immunotherapy, Nanoparticles, scaffolds, solid tumors, T-cell activation, t-cells
Category(s): Platforms > Drug Delivery > Nanoparticles
An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....
Published: 2/14/2025   |   Inventor(s): Otto Yang
Keywords(s): Anti-CD3 antibodies, Bispecific antibodies, CD8 T cells, Human cytomegalovirus (CMV), immunocompromised patients, Immunotherapy, Lymphocytes, T cell redirecting bispecific antibody (TRBA), Transplant, Viral infection
Category(s): Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy
Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)
UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...
Published: 2/14/2025   |   Inventor(s): Roger Lo
Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)
UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...
Published: 2/14/2025   |   Inventor(s): Bin Liu, Steven Dubinett
Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary
1 2 3 4 5 6 7 8 9 10 ...